Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.
Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.
As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.
The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.
The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.
Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.
Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.
The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.
Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.
A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.